Medical company, St. Jude Medical, Inc.(
) saw a sharp decline Tuesday, after concern with recent heart
The company's stock fell 12% after news that major flaws were
found in their testing and oversight of a heart device, and how
inspections are done on its products.
The FDA has been focusing on one of the company's products
called Durata, which is a electrial wite that connects an implanted
defibrillator to a patients heart. In this product, the company
uses a material called Optim, but now the FDA is questioning the
company about the quality and effectiveness of the material
The company has been in the spotlight for a few months since the
failure of a product called Riata. However, STJ is insisting that
Durata is a safe product, going against FDA recommendation that
patients wait until the product's safety is further proven.
St. Jude shares were down $4.36, or -12.27% during Wednesday
afternoon trading. The stock is down 8.6% YTD.
The Bottom Line
Shares of St.Jude Medical, Inc (
) have a 2.58% dividend yield, based on last night's closing stock
price of $35.71. The stock has technical support in the $27-$28
price area. If the shares can firm up, we see overhead resistance
around the $36 price level.
St. Jude Medical, Inc.(
) is not recommended at this time, holding a Dividend.com DARS™
Rating of 3.1 out of 5 stars.
Be sure to visit our complete recommended list of the
Best Dividend Stocks
, as well as a detailed explanation of
our ratings system here
Created by Dividend.com